Particula | $5,500,000 | (May 1, 2025)
Stimuler | $3,750,000 | (May 1, 2025)
SpriveApp | $7,300,000 | (May 1, 2025)
Certified by Founder
Lodge
ADARx Pharmaceuticals Inc.
start up
United States
- San Diego, CA
- 10/08/2023
- Series C
- $200,000,000
ADARx Pharmaceuticals, Inc., located in San Diego, is a clinical stage biotechnology company committed to turning cutting-edge science into life-saving therapeutics. ADARx has developed proprietary RNA targeting platforms and oligonucleotide delivery technologies for inhibition, degradation, and editing disease-causing mRNA. ADARx has a growing pipeline of RNA targeting therapeutics for treating diseases across a range of therapeutic areas including genetic, cardiometabolic, complement-mediated diseases and central nervous system diseases. We are well-financed by a syndicate of renowned VC firms.
ADARx currently has multiple active programs in development. Our lead candidate is at the clinical stage.
- Industry Biotechnology Research
- Website https://www.adarx.com/
- LinkedIn https://www.linkedin.com/company/adarx-pharmaceuticals-inc/
Manifest | $15,000,000 | (May 1, 2025)
Spark Biomedical Inc | $15,000,000 | (May 1, 2025)
Queens Carbon | $10,000,000 | (May 1, 2025)
Noma Therapy | $4,250,000 | (May 1, 2025)
Persona | $200,000,000 | (May 1, 2025)
Nuvo | $45,000,000 | (May 1, 2025)
Pallie | $2,000,000 | (May 1, 2025)
Faye(US) | $2,500,000 | (May 1, 2025)
Structify | $4,100,000 | (May 1, 2025)